Kaitlin
Soye, PhD
she / her / hers
Partner
Kaitlin is an intellectual property lawyer who enjoys collaborating with clients to develop effective IP strategies. As a trained scientist with a PhD in experimental medicine, she is adept at fusing legal and scientific principles to devise creative solutions to complex problems.
Kaitlin is member of the firm’s Intellectual Property and Litigation & Dispute Resolution Groups and a Co-Leader of the firm's Life Sciences Group. She represents a broad range of clients, including pharmaceutical, life sciences, technology and telecommunication companies, specifically with regulatory and IP litigation needs.
Kaitlin has extensive Federal Court experience and is efficient at managing the challenges that accompany complex litigation. She leverages her scientific background to represent life sciences and pharmaceutical industry clients in patent and regulatory disputes.
Professional Involvement
Memberships
- Member-at-Large, Intellectual Property Law Section, Canadian Bar Association
- Indigenous IP Committee, Intellectual Property Institute of Canada
- Pharmaceutical & Biotechnology Issues Committee, Intellectual Property Owners Association
- Law Society of Ontario
- Mentorship Program, Toronto Intellectual Property Group
- Mentorship Program, First Generation Network
Litigation Committee, Intellectual Property Institute of Canada, 2021-Present
Law Society of Ontario
The Advocates’ Society
Member-at-Large, Information Technology and Intellectual Property Law Executive, Ontario Bar Association
Toronto Intellectual Property Group
Mentorship Program, First Generation Network
Moderator, "EDI Through the Ages: Are We There Yet?" CBA IP Day Session, May 29, 2025.
Panellist, "Bifurcation Motions in Intellectual Property Disputes," CBA Session, October 21, 2024.
Presenter, "Intellectual Property: Key Concepts & Considerations," Seneca College Business Law Presentation, March 20, 2024.
Presenter, "Anatomy of a Patent Trial," ILCO’s Advanced Litigation Law CLE Program, November 20, 2019.
Speaker, "OCI Demystified 2019," Winsor Law’s OCI Demystified event, July 12, 2019.
Co-Author, "AI Comes to Court in Canada," Internet and Technology Law in Canada, April 2026.
Co-Author, "Federal Court Imposes Jail Time in Copyright Infringement Case," Aird & Berlis LLP, The Spotlight, September 9, 2025.
Co-Author, "Patents and Prior Art: Federal Court Clarifies Standards for Anticipation and Obviousness," Aird & Berlis LLP, The Spotlight, July 14, 2025.
Co-Author, "Important New Procedural Guidelines From the PMPRB," Aird & Berlis LLP, The Spotlight, July 8, 2025.
Co-Author, "Due Care in Action: Critical Factors in Canadian Patent Reinstatement and Expiry Cases," Aird & Berlis LLP, The Spotlight, April 9, 2025.
Author, "PMPRB’s Jurisdiction Limited to Patented Medicines," Aird & Berlis LLP, The Spotlight, December 5, 2024.
Author, "Federal Court Invalidates Patents for Ambiguity," Aird & Berlis LLP, The Spotlight, July 9, 2024.
Author, "Update from the FCA on Standard of Review for Claims Construction," Ontario Bar Association: Information Technology and Intellectual Property Law, May 2, 2024.
Author, "The Mountains Are Calling – Rare Interlocutory Injunction in Outdoor Apparel Trademark Dispute," Aird & Berlis LLP, The Spotlight, January 4, 2024.
Co-Author, "Direction From the Court on the Role of Expert Witnesses in Patent Cases," Aird & Berlis LLP, Intellectual Property Flash, July 11, 2023.
Author, "Five Tips For Working With Self-Represented Litigants in IP Matters," Ontario Bar Association: Information Technology and Intellectual Property Law, February 25, 2023.
Author, “Digging into the 2022 Federal Budget: Intellectual Property Issues,” Ontario Bar Association: Information Technology and Intellectual Property Law, May 7, 2022.
Co-Author, “Motions to Inspect Documents on Property,” Intellectual Property Litigation: Forms and Precedents, April 19, 2016.
Co-Author, “In vitro inhibition of mumps virus by retinoids,” Virology Journal, 2013 Nov 14;10:337, November 14, 2013.
Co-Author, “Genotype-driven recruitment: a strategy whose time has come?,” BMC Med Genomics 6, 19, May 23, 2013.
Co-Author, “RIG-I is required for the inhibition of measles virus by retinoids,” PLOS ONE 6(7), July 19, 2011.
Co-Author, “In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication,” RNA Biol 2011, March 1, 2011.
Co-Author, “Inhibition of HIV-1 expression and replication by SOFA-HDV ribozymes against Tat and Rev mRNA sequences,” Retrovirology 2009, September 24, 2009.
Co-Author, “Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production,” Virology Journal, March 14, 2007.